<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164900">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02023697</url>
  </required_header>
  <id_info>
    <org_study_id>16507</org_study_id>
    <secondary_id>2013-003118-42</secondary_id>
    <nct_id>NCT02023697</nct_id>
  </id_info>
  <brief_title>Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone</brief_title>
  <official_title>A Three Arm Randomized Open-label Phase II Study of Radium-223 Dichloride 50 kBq/kg Versus 80 kBq/kg, and Versus 50 kBq/kg in an Extended Dosing Schedule in Subjects With Castration-resistant Prostate Cancer Metastatic to the Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Chile: Instituto de Salud Pública de Chile</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess different doses and regimens of radium-223 dichloride on the
      incidence of symptomatic skeletal events. Eligible subjects must have castration resistant
      prostate cancer with 2 or more skeletal metastases documented within 8 weeks of
      randomization. Subjects will be randomized to one of 3 treatment arms in a 1:1:1 fashion: a
      standard regimen of radium-223 dichloride of 50 kBq/kg injections every month for 6 months,
      a high dose regimen of 80 kBq/kg injections every month for 6 months or an extended duration
      regimen of 50 kBq/kg injections every month for 12 months. Following the treatment phase,
      subjects will be followed up every 12 weeks for a minimum of 2 years, at which point they
      will enter a long term follow-up period during which they are seen every 6 months for up to
      7 years after the last dose of radium dichloride. Symptomatic skeletal event and safety
      endpoints will be assessed at each clinic visit. Pain and analgesic use data will be
      collected every 4 weeks through Week 48. Additionally, radiological assessments including
      MRI/CT of the abdomen and pelvis and chest CT, as well as technetium-99 bone scans will be
      performed at Weeks 8, 16, and 24 and continue every 12 weeks thereafter until disease
      progression is documented in either the bone or in soft tissue. Radiological imaging will be
      evaluated by blinded central review.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Symptomatic skeletal event-free survival</measure>
    <time_frame>From randomization up to a maximum of 8 years, assessed every month during treatment and every 12 weeks during active follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization up to a maximum of 8 years, assessed every month during treatment and every 12 weeks during active follow-up and every 6 months in long term follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first symptomatic skeletal event</measure>
    <time_frame>From randomization up to a maximum of 8 years, assessed every month during treatment and every 12 weeks during active follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological progression free survival</measure>
    <time_frame>From randomization up to a maximum of 3 years, assessed  at Weeks 8, 16, and 24 and continue every 12 weeks thereafter until disease progression is documented in either the bone or in soft tissue</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radiological progression</measure>
    <time_frame>From randomization up to a maximum of 3 years, assessed  at Weeks 8, 16, and 24 and continue every 12 weeks thereafter until disease progression is documented in either the bone or in soft tissue</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain improvement rate, defined as the number of subjects with pain improvement divided by the total number of subjects evaluable for pain improvement</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by Worst Pain Score (WPS) on the Brief Pain Inventory Short Form (BPI-SF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessed by Worst Pain Score (WPS) on the Brief Pain Inventory Short Form (BPI-SF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events or serious adverse events as a measure of safety and tolerability</measure>
    <time_frame>From randomization up to 8 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Includes acute and long-term safety, myelo suppression and additional primary malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour analgesic use</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Radium-223 dichloride (Standard dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radium-223 dichloride (High dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 80 kBq/kg body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radium-223 dichloride (Extended standard dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection to be administered every 4 weeks up to 12 injections. The dose per injection is 50 kBq/kg body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 dichloride (Xofigo, BAY88-8223)</intervention_name>
    <arm_group_label>Radium-223 dichloride (Standard dose)</arm_group_label>
    <arm_group_label>Radium-223 dichloride (High dose)</arm_group_label>
    <arm_group_label>Radium-223 dichloride (Extended standard dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Castration-resistant disease defined as:

               -  Serum testosterone level: ≤ 50 ng/dL (1.7 nmol/L)

               -  Bilateral orchiectomy or maintenance on androgen ablation therapy with
                  luteinizing-hormone-releasing hormone (LHRH) agonist or antagonist, or
                  polyestradiol phosphate

               -  Serum PSA (Prostate specific antigen) progression defined as 2 subsequent
                  increases in PSA over a previous reference value (a minimum of 2 ng/mL [μg/L])
                  OR

               -  Radiographic evidence of disease progression in bone (according to Prostate
                  Cancer Clinical Trials Working Group 2 [PCWG2] criteria) with or without PSA
                  progression

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2. In case of
             ECOG PS 2, the PS has to be due to metastatic prostate cancer to the bone.

          -  Two or more skeletal metastases (≥ 2 hot spots) on bone scintigraphy within 8 weeks
             of randomization

        Exclusion Criteria:

          -  History of visceral metastasis, or visceral metastases

          -  Lymphadenopathy with lymph nodes exceeding 3 cm in short axis diameter

          -  Central nervous system (CNS) metastases

          -  Treatment with cytotoxic chemotherapy for prostate cancer within the previous 4 weeks
             prior to randomization, or planned treatment with cytotoxic chemotherapy agents for
             prostate cancer during the treatment period or follow-up

          -  Chronic conditions associated with non-malignant abnormal bone growth (e.g. confirmed
             Paget's disease of bone)

          -  Prior treatment with radium-223 dichloride

          -  Prior systemic radiotherapy and hemibody external radiotherapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For trial location information (Phone Menu Options '3' or '4')</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040-1496</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90470 340</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chomutov</city>
        <zip>430 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seinäjoki</city>
        <zip>60220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Hashomer</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Meldola</city>
        <state>Forlì</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Baleares</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Guishan Township</city>
        <state>Taoyuan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>December 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Succinylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
